Here's the short version before we dig into details:

BPC-157 and TB-500 already left the FDA's Category 2 restricted list on April 23, 2026 — when the companies that originally nominated them for that list withdrew their nominations. The FDA's Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to formally review 7 of these compounds for inclusion on the 503A Bulks List, which would create the official pathway for licensed compounding pharmacies to prepare them under physician prescription.

This is the biggest regulatory shift in the peptide compounding space since the original Category 2 designations in 2023–2024. It's part of a broader 2026 trend — while compounded research peptides like BPC-157 are returning to the compounding pathway, SS-31 (Forzinity) became the first mitochondrial peptide to clear full FDA accelerated approval last September. Different pathways, same direction.

What Category 2 Was — and What Leaving It Means

Between late 2023 and December 2024, the FDA moved 19 popular peptides from Category 1 to Category 2 on the 503A Bulk Drug Substances list. Category 2 means a substance has been identified as presenting significant safety risks that make it ineligible for routine compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

In practical terms: Category 2 = licensed compounding pharmacies cannot legally prepare these compounds for patients, even with a physician's prescription.

Leaving Category 2 doesn't automatically mean a compound is approved for compounding. It means the legal barrier to consideration has been removed. The next step — the July 23–24 PCAC meeting — is where the FDA's advisory committee reviews specific compounds and recommends whether they should be formally placed on the 503A Bulks List, which is the affirmative approval for compounding pharmacy use.

What Happened on April 23, 2026

The mechanism wasn't a formal FDA reclassification vote. The companies that originally nominated these peptides for the Category 2 list withdrew those nominations. When nominations are withdrawn, the compounds come off Category 2. It's procedural, but it's real.

On the Joe Rogan Experience (Episode #2461), HHS Secretary Robert F. Kennedy Jr. stated that approximately 14 of the 19 previously restricted peptides would be moving back to legal compounding status. That statement described the directional outcome of the nomination withdrawal process — but the formal regulatory mechanism was the withdrawals themselves, effective April 23, 2026.

What Secretary Kennedy described as the intended outcome and what the FDA's procedural pathway produces are aligned. But it's important to understand the actual mechanism: nomination withdrawals removed the Category 2 designation; the July PCAC meeting determines 503A Bulks List inclusion.

The July 23–24, 2026 PCAC Meeting: What's Actually on the Agenda

From the FDA's official advisory committee calendar (fda.gov), here is the exact agenda:

July 23, 2026 — Four compounds reviewed:

| Compound | Use(s) Being Evaluated | |---------|----------------------| | BPC-157 (free base / acetate) | Ulcerative colitis (UC) | | KPV (free base / acetate) | Wound healing and inflammatory conditions | | TB-500 (free base / acetate) | Wound healing | | MOTS-c (free base / acetate) | Obesity and osteoporosis |

July 24, 2026 — Three compounds reviewed:

| Compound | Use(s) Being Evaluated | |---------|----------------------| | Emideltide / DSIP (free base / acetate) | Opioid withdrawal, chronic insomnia, narcolepsy | | Semax (free base / acetate) | Cerebral ischemia, migraine, trigeminal neuralgia | | Epitalon (free base / acetate) | Insomnia |

Total: 7 compounds across 2 days.

Docket for public comment: FDA-2026-N-2979 (comments accepted until July 22, 2026)

The PCAC's recommendations are non-binding — the FDA generally follows them but is not legally required to. A positive recommendation would put these compounds on the 503A Bulks List, formally enabling licensed compounding pharmacies to prepare them under physician prescription.

What This Means — and What It Doesn't Mean

What it means:

BPC-157, TB-500, and Epitalon are no longer on the Category 2 restricted list as of April 23, 2026
Licensed compounding pharmacies are actively evaluating when and how to resume offering these compounds
The July PCAC meeting will determine whether these compounds get formal 503A Bulks List placement
A positive PCAC outcome followed by FDA finalization (estimated fall 2026) would restore the full legal compounding pathway under physician supervision

What it doesn't mean:

This is not FDA approval of these compounds for human use — that's a different process involving full clinical trials and NDA submission
This is not a guarantee — the PCAC could recommend against inclusion, and the FDA could delay or decline to finalize
"Category 1" is colloquial shorthand — the formal designation is "nominated for inclusion on the 503A Bulks List"

The Regulatory Landscape: Two Simultaneous Moves in Opposite Directions

It's worth noting the context: while research peptides are getting easier to access through compounding pharmacies, GLP-1 drugs face the opposite trajectory. On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — ending large-scale compounding of these drugs. The comment period closes June 29, 2026.

Research peptides: regulatory restrictions easing. Compounded GLP-1s: regulatory restrictions tightening.

Both developments have significant implications for anyone optimizing their health protocol in 2026. Understanding where each compound stands is exactly why accurate, current information matters — and why we update PeptidesGPT's AI Coach as regulatory status changes.

What This Means for Your Protocol

If BPC-157 or TB-500 is part of your protocol — or you've been waiting for legal compounding access to return — the picture is clearer now:

The Category 2 barrier is gone as of April 23
Formal 503A approval is under review at the July 23–24 PCAC meeting
Clinical compounding access — if the PCAC recommends inclusion and the FDA finalizes — is likely available fall 2026

PeptidesGPT's AI Coach has been updated to reflect the current regulatory status of all seven compounds under PCAC review. If you have questions about how these developments affect your specific protocol, ask the Coach.

Key sources (all publicly available):

FDA Advisory Committee Calendar: fda.gov/advisory-committees — July 23–24, 2026 PCAC Meeting
FDA-2026-N-2979 (PCAC docket) / FDA-2025-N-6895 (public comment docket)
FDA Press Release, April 30, 2026 — semaglutide/tirzepatide/liraglutide 503B proposal
Federal Register Docket 2026-08552
RFK Jr., Joe Rogan Experience Episode #2461

For educational purposes only. PeptidesGPT is not a medical provider and does not provide legal or regulatory advice. Regulatory status is based on publicly available FDA announcements and is subject to change. Always consult a qualified healthcare provider and licensed compounding pharmacy for guidance specific to your situation.